A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Exclusion Criteria

• •1. Received TURBT or other surgical treatment or radiotherapy for bladder lesions within 2 weeks before the first administration;
• •2. Patients who were receiving treatment in other clinical trials or less than 4 weeks from the end of the first administration in this study;
• •3. History of serious cardiovascular and cerebrovascular diseases;
• •4. Severe infection within 2 weeks prior to the first dose;
• •5. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0;
• •6. Oversize surgery or severe trauma within 4 weeks before the first use of research drugs;
• •7. Previously received any TNFR agonist antibody therapy, such as OX40, CD137, CD27, CD357 antibodies.